Dynamic Technology Lab Private Ltd purchased a new position in shares of Cryolife Inc (NYSE:CRY) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 19,221 shares of the medical equipment provider’s stock, valued at approximately $561,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of CRY. Arizona State Retirement System raised its holdings in Cryolife by 6.7% in the fourth quarter. Arizona State Retirement System now owns 52,376 shares of the medical equipment provider’s stock valued at $1,486,000 after buying an additional 3,283 shares during the period. Advisors Asset Management Inc. purchased a new stake in shares of Cryolife during the fourth quarter valued at approximately $32,000. Rhumbline Advisers raised its stake in shares of Cryolife by 23.7% during the fourth quarter. Rhumbline Advisers now owns 99,844 shares of the medical equipment provider’s stock valued at $2,834,000 after purchasing an additional 19,137 shares during the period. LS Investment Advisors LLC raised its stake in shares of Cryolife by 126.0% during the fourth quarter. LS Investment Advisors LLC now owns 2,581 shares of the medical equipment provider’s stock valued at $73,000 after purchasing an additional 1,439 shares during the period. Finally, Oregon Public Employees Retirement Fund purchased a new stake in shares of Cryolife during the fourth quarter valued at approximately $367,000. Institutional investors own 71.20% of the company’s stock.
In other Cryolife news, CEO James P. Mackin sold 50,000 shares of Cryolife stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $31.31, for a total value of $1,565,500.00. Following the completion of the transaction, the chief executive officer now owns 220,731 shares of the company’s stock, valued at $6,911,087.61. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Scott B. Capps sold 2,000 shares of the business’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $28.55, for a total transaction of $57,100.00. Following the transaction, the vice president now directly owns 141,079 shares of the company’s stock, valued at approximately $4,027,805.45. The disclosure for this sale can be found here. Insiders have sold 99,609 shares of company stock valued at $3,112,863 in the last three months. Corporate insiders own 4.40% of the company’s stock.
CRY stock opened at $29.20 on Wednesday. Cryolife Inc has a twelve month low of $23.99 and a twelve month high of $36.05. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.90 and a quick ratio of 3.69. The company has a market cap of $1.10 billion, a PE ratio of 112.31 and a beta of 0.61.
Cryolife (NYSE:CRY) last released its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.04 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.04. Cryolife had a negative net margin of 0.09% and a positive return on equity of 3.79%. The business had revenue of $67.50 million during the quarter, compared to the consensus estimate of $66.37 million. During the same quarter last year, the company earned $0.02 earnings per share. The business’s quarterly revenue was up 9.0% compared to the same quarter last year. On average, analysts anticipate that Cryolife Inc will post 0.31 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://dakotafinancialnews.com/2019/06/12/dynamic-technology-lab-private-ltd-purchases-shares-of-19221-cryolife-inc-nysecry.html.
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Further Reading: Trading signals using Bollinger bands
Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryolife Inc (NYSE:CRY).
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.